18 and older, any sex, with Recurrent Glioblastoma or Recurrent Astrocytoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Patients Who Experience Adverse EventsPrimary· Up to 17 months
Number of patients who experience adverse events with individualized starting dose (ISD) of niraparib using CTCAE v5.0
Group
Value
95% CI
Niraparib Treatment
9
Efficacy of Treatment in Dose Expansion PhasePrimary· up to 12 months
Percentage of patients who respond to niraparib monitored by disease control rate (stable disease and better) using RANO from start of treatment for up to 12 months.
Group
Value
95% CI
Niraparib Treatment
0
Number of Patients Who Experience Toxicities With Individualized Starting Dose (ISD) of Niraparib Using CTCAE v5.0Primary· 5 months
Number of patients who experience toxicities (defined as grade 3 or 4 adverse events) with individualized starting dose (ISD) of niraparib using CTCAE v5.0
Group
Value
95% CI
Niraparib Treatment
5
Progression Free Survival in Dose Expansion PhaseSecondary· 20 months
Proportion of patients who have progression-free survival from date of study entry until the first documented date of progression or date of death, whichever comes first.
Group
Value
95% CI
Niraparib Treatment
1.62
1.06 – NA
Overall Survival in Dose Expansion PhaseSecondary· 20 months
Proportion of patients with overall survival on the study defined as time from date of study entry to death by any cause.
Group
Value
95% CI
Niraparib Treatment
10.81
4.63 – NA
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected for 17 months..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
· Phase 4
· recruiting
NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
· Phase 1, PHASE2
· recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
· Phase 3
· recruiting
NCT06887933 — A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ov
· Phase 4
· not yet recruiting
NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
· Phase 1, PHASE2
· withdrawn
Other recruiting trials for Recurrent Glioblastoma
Currently open trials in the same condition.
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
· Phase 1
· recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
· Phase 1
· recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
· NA
· recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
· Phase 1
· recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P
· EARLY_PHASE1
· recruiting
Other University of Oklahoma trials
Trials by the same sponsor.
NCT07219706 — Dietary Fiber and Time Restricted Eating
· NA
· recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection
· Phase 1, PHASE2
· not yet recruiting
NCT07014605 — Smoking Cessation Program for Lao People With HIV
· NA
· not yet recruiting
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
· recruiting
NCT07491653 — Fiber mHealth Intervention for Prediabetes
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05297864.